55P PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients
Hendriks B, Shields A, Siegel B, Miller K, Munster P, Ma C, Campbell K, Moyo V, Wickham T, LoRusso P. 55P PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients. Annals Of Oncology 2014, 25: i19. DOI: 10.1093/annonc/mdu068.1.Peer-Reviewed Original ResearchHER2-positive breast cancer patientsBreast cancer patientsPET/CT imagingCancer patientsLiposomal doxorubicinTumor lesionsCT imagingLiposomal drug delivery